Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFT5-SMPT-dgA for GVHD Prevention in Stem Cell Transplant
NCT00025662Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- May 2001
- Primary completion
- Feb 2008
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RFT5-SMPT-dgA in graft-versus-host disease (GVHD), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Treatment-related Mortality at 100 days. Started May 2001; status: completed.
02
Drugs
RFT5-SMPT-dgA
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00025662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025662.